Objective:To explore the changes of the expression of AFPmRNA and MAGE-1mRNA and the effect of liver function and quality of life in primary hepatocellular carcinoma(PHC) after oral Pingtiaoyin therapy , so as to provide experimental foundations to the clinical appliance of pingtiaoyin.Methods: 60 patients with PHC were divided into two groups randomly,treatment group(n=30) and control group(n=30). oral Pingtiaoyin therapy and Injection of Huachansu was accepted two course of medical treatments in treatment group and control group . RT-PCR was used to detect AFPmRNA and MAGE-1mRNA expression in peripheral blood of patients before and after treatment , and 30 healthy volunteers were selected as the control . At the same time, the liver function and physical status score of patients were compared before and after treatment .The data was processed by statistics of software spss13.0 .Results:①The expression of AFPmRNA and MAGE-1mRNA were markedly decreased after oral Pingtiaoyin therapy .There was significant differences before and after treatment in two groups (P<0.01). The brightness ratio of the strap of MAGE-1 vsβ-actin after treatment in the treatment group and the control group was 0.07±0.01VS0.13±0.02(P<0.01),and the result of the treatment group was better than that of the control group obviously .②AST and ALT levels of two groups in serum were decreased obviously than before treatmen(tP<0.05), while liver function other indexes were no significant differences after treatment (P>0.05).③Improvement ratio of the physical condition was 43.33% in Pingtiaoyin group, higher than control group(36.67%), However, the improvement rate,stable rate and lower rate was no statistical difference between the two groups(P>0.05 ).Conclusion:①The expression of AFPmRNA and MAGE-1mRNA were markedly decreased after oral Pingtiaoyin therapy.②Pingtiaoyin can effectively reduce AST and ALT levels in serum of the patients with PHC .③Pingtiaoyin can improve the physical status of patients with middle-late primary hepatocellular carcinoma and improve the quality of life of patients.
|